Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
Over years or decades, hepatitis C can lead to serious complications.
Hepatitis C virus (HCV) is the most common blood-borne virus in the United States.
These recommendations are based on the World Health Organization’s guidelines.
On the whole, lean individuals had lower prevalence for these conditions than people with overweight or obesity.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
In these women, higher testosterone ramped up the likelihood of abdominal fat buildup.
Women also had a higher rate of hepatocellular carcinoma in the absence of cirrhosis.
No significant links were found between liver stiffness prior to antiviral treatment and cirrhosis, liver cancer or transplants or death.
A daily dose of the growth factor analogue administered over 24 weeks also aided in NASH resolution.
Using a two-part testing plan could help identify those with advanced liver fibrosis among people with type 2 diabetes.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
Researchers suggest the process is safe and may help reduce alcohol cravings.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
Researchers reported significant changes in liver, cardiovascular and diabetes markers.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.